Frontmasta
17.11.2017 kl 00:46
1675

For innrulering til Lymrit 37 02 gjelder følgende......

If amount of tumour cells is still above 25% after rituximab pre-treatment, the patient will need to be excluded from the study prior to HH1 infusion and Betalutin administration.
Arkivert